Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986278 Drug Interaction Study with Itraconazole, Gemfibrozil, or Carbamazepine
NCT05932303Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2023
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of admilparant in idiopathic pulmonary fibrosis (IPF) and pulmonary fibrosis (PF) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration (Cmax) up to 33 days, Area under the plasma concentration-time curve from time zero to time of the last quantifiable concentration (AUC[0-T]) up to 33 days and 1 more. Started Jul 2023; status: completed.
02
Drugs
admilparant
03
Conditions
idiopathic pulmonary fibrosis (IPF)pulmonary fibrosis (PF)
Beyond the preview
Go deeper on NCT05932303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05932303.